

Supplementary Table.

References: (I): Intensive production; (B): Backyard production; (MAR index) Multiple antibiotic resistance index; (VI) Virulence genes index; (LN): Mesenteric lymph nodes.

Isolate	Serotype	Source	Type of production	Location	Year	Antibiotic resistance profiles	MAR index	Virulence genes	VI
88	Agona	Feaces	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
87	Agona	LN	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-bcfC</i>	0,5
82	Agona	Feaces	I	Bs. As.	2013		0	<i>sopB-ssaQ-mgtC-avrA-sodC1-siiD-bcfC</i>	0,7
84	Agona	Gallbladder	I	Bs. As.	2013	AMP-CLR-TET-NAL	0,27	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
113	Agona	Feaces	I	Bs. As.	2012	CLR-TET-NAL	0,20	<i>sopB-ssaQ-mgtC-avrA-siiD</i>	0,5
98	Anatum	Gallbladder	I	Bs.As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
99	Anatum	Feaces	I	Bs.As.	2014		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
111	Anatum	Feaces	I	Bs.As.	2013		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
12/18-465	Bredeney	Feaces	B	Bs.As.	2018		0	<i>sopB-ssaQ-mgtC-avrA-siiD</i>	0,5
165/17-H	Cerro	Feaces	I	Bs.As.	2017	AMP-CEP-CLR-TET-NAL-ENR	0,40	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
165/17-P	Cerro	Feaces	I	Bs.As.	2017	AMP-TMS-CLR-TET-NAL-ENR	0,40	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
78	Cholerasuis	Feaces	I	Bs.As.	2012		0	<i>sopB-ssaQ-avrA-siiD-bcfC</i>	0,5
2335/17 MJ	Cholerasuis	LN	I	Cordoba	2017	TMS-TET	0,13	<i>sopB-ssaQ-mgtC-spvC-sodC1-siiD-bcfC</i>	0,7
93	Derby	Gallbladder	I	Bs.As.	2013	AMP-CLR-TET-NAL	0,27	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
89	Derby	Feaces	I	Bs.As.	2013	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
85	Derby	Feaces	I	Bs.As.	2013	CLR-NAL	0,13	<i>sopB-ssaQ-mgtC-avrA-sodC1-bcfC</i>	0,6

2344/17 MJ	Derby	Feaces	I	Cordoba	2017		0	<i>sopB-ssaQ-mgtC-avrA-sopE1-siiD-bcfC</i>	0,7
174/17-3	Derby	Feaces	I	Bs. As.	2017	AMP-CEP-CFO-CLR-TET-NAL-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
133/18-C	Derby	Feaces	I	Misiones	2018	AMP-CLR-TET-NAL	0,27	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
12/18-464	Enteritidis	Feaces	B	Bs. As.	2018		0	<i>sopB-ssaQ-mgtC-avrA-siiD</i>	0,5
12/18-466	Lille	Feaces	B	Bs. As.	2018		0	<i>sopB-ssaQ-mgtC-siiD</i>	0,4
26/17	Lindenburg	Feaces	B	Bs. As.	2017	AMP-CFO-CLR-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-sodC1-sopE1-siiD-bcfC</i>	0,8
96	Liverpool	LN	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
97	Liverpool	Gallbladder	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
100	Liverpool	Gallbladder	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
114/17-G16	Mbandaka	Feaces	I	Santa Fe	2017	AMP-TMS-CLR-TET	0,27	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
31/17	Newport	Feaces	I	Bs. As.	2017	CFTIO	0,07	<i>sopB-ssaQ-mgtC-avrA-sodC1-sopE1-siiD-bcfC</i>	0,8
12/18-463	Newport	Feaces	B	Bs. As.	2018		0	<i>sopB-ssaQ-mgtC-avrA-sopE1-siiD</i>	0,6
174/17-5	Ohio	Feaces	I	Bs. As.	2017	AMP-CFO-CLR-TET-NAL-ENR	0,40	<i>sopB-ssaQ-mgtC-siiD-bcfC</i>	0,5
174/17-6	Ohio	Feaces	I	Bs. As.	2017	AMP-CLR-TET-ENR	0,27	<i>sopB-ssaQ-mgtC-siiD-bcfC</i>	0,5
83	Rissen	Feaces	I	Bs. As.	2013	CLR-ENR	0,13	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-siiD-bcfC</i>	0,8
86	Rissen	Feaces	I	Bs. As.	2013	CLR-ENR	0,13	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-bcfC</i>	0,7
79	Rissen	Feaces	I	Bs. As.	2012	CLR-ENR	0,13	<i>sopB-ssaQ-mgtC-avrA-</i>	0,6

								<i>sodC1-siiD</i>	
291/16	Rissen	Feaces	B	Bs. As.	2016	TMS-ENR	0,13	<i>sopB-ssaQ-mgtC-avrA-sodC1-sopE1-siiD-bcfC</i>	0,8
108	Schwarzengrund	Gallbladder	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
110	Schwarzengrund	Gallbladder	I	Bs. As.	2012	GEN-CLR-TET	0,20	<i>sopB-ssaQ-mgtC-avrA-sodC1-siiD</i>	0,6
105/17-1	Schwarzengrund	Feaces	B	Bs. As.	2017		0	<i>sopB-ssaQ-mgtC-avrA-bcfC</i>	0,5
105/17-2	Schwarzengrund	Feaces	B	Bs. As.	2017		0	<i>sopB-ssaQ-mgtC-avrA-bcfC</i>	0,5
12/18-467	Schwarzengrund	Feaces	B	Bs. As.	2018		0	<i>sopB-ssaQ-mgtC-avrA-sopE1-siiD</i>	0,6
12/18-468	Stanleyville	Feaces	B	Bs. As.	2018		0	<i>sopB-ssaQ-mgtC-avrA-sopE1-siiD</i>	0,6
95	Thompson	LN	I	Santa Fe	2013	TET-NAL	0,13	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
175	Typhimurium	LN	I	Bs. As.	2013	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-siiD-bcfC</i>	0,8
183	Typhimurium	Gallbladder	I	Bs. As.	2012	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-siiD-bcfC</i>	0,8
90	Typhimurium	LN	I	Bs. As.	2013	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-siiD-bcfC</i>	0,8
94	Typhimurium	Gallbladder	I	Bs. As.	2012	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-sodC1-siiD-bcfC</i>	0,7
186	Typhimurium	LN	I	Bs. As.	2013	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-sodC1-siiD-bcfC</i>	0,7
2351/17 MJ	Typhimurium	Feaces	I	Cordoba	2017	AMP-CEP-TMS-GEN-CLR-TET-NAL-CIPR-ENR	0,60	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-sopE1-siiD-bcfC</i>	0,9
165/17-ABC	Typhimurium	Feaces	I	Bs. As.	2017	AMP-CEP-CLR-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-siiD-bcfC</i>	0,8

165/17-EFG	Typhimurium	Feaces	I	Bs. As.	2017	AMP-CEP-GEN-CLR-TET-NAL-CIPR-ENR	0,53	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-siiD-bcfC</i>	0,8
197/17-A	Typhimurium	LN	B	Bs. As.	2017	AMP-CEP-GEN-TET-NAL-ENR	0,40	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-sopE1-siiD-bcfC</i>	0,9
194/17-E	Typhimurium	Feaces	I	Neuquen	2017	AMP-CEP-GEN-TET-NAL-ENR	0,40	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-sopE1-siiD-bcfC</i>	0,9
194/17-G	Typhimurium	Feaces	I	Neuquen	2017	AMP-CEP-GEN-TET	0,27	<i>sopB-ssaQ-mgtC-avrA-spvC--sodC1-siiD-bcfC</i>	0,8
04/18-A	Typhimurium	Feaces	I	Bs. As.	2018	CFTIO-TET	0,13	<i>sopB-ssaQ-mgtC-avrA-spvC-sodC1-siiD</i>	0,7
64	(4,12:i:-)	Gallbladder	I	Bs. As.	2012	AMP-CEP-CFX-CFTIO-FEP-TMS-GEN-TET-NAL-CIPR-ENR-AZT	0,80	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-sopE1-siiD-bcfC</i>	0,9
92	(4,12:i:-)	Gallbladder	I	Bs. As.	2012	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-gipA-sodC1-siiD-bcfC</i>	0,8
63	(4,12:i:-)	Gallbladder	I	Bs. As.	2012	AMP-TMS-GEN-TET-NAL-CIPR-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-sodC1-siiD-bcfC</i>	0,7
81	Westhampton	LN	I	Bs. As.	2012		0	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
165/17-D	Worthington	Feaces	I	Bs. As.	2017	AMP-CEP-GEN-CLR-TET-NAL-ENR	0,47	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6
165/17-MNO	Worthington	Feaces	I	Bs. As.	2017	AMP-CLR-TET-NAL-ENR	0,33	<i>sopB-ssaQ-mgtC-avrA-siiD-bcfC</i>	0,6